Lipum gets approval to start Phase 1 clinical trial with drug candidate SOL-116
Press release: Umeå, 27 September, 2022. Lipum AB (publ) announces today that the CTA (clinical trial application) for the drug candidate SOL-116 has been approved by the regulatory authorities in The Netherlands.The study that includes healthy volunteers and patients with rheumatoid arthritis will be carried out at QPS BV facility in Groningen, Netherlands. The study [...]